We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth

Simply Wall StMar 27 11:26 ET

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BusinesswireMar 13 16:05 ET

Express News | Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

ReutersMar 13 16:05 ET

Morgan Stanley Maintains Contineum Therapeutics(CTNM.US) With Hold Rating, Maintains Target Price $14

Moomoo NewsMar 10 07:31 ET · Ratings

JonesTrading Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Raises Target Price to $26

Moomoo NewsMar 9 06:32 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Contineum Therapeutics, Inc. Class A (CTNM) and Aktis Oncology, Inc. (AKTS)

TipRanksMar 9 06:30 ET · Ratings